ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024

TOULOUSE, France, LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today provides an update on its activity and cash position as of March 31, 2024. Selected financial information (IFRS) €m Q1 2024 Q1 2023 Revenue from biotech activity 0.00 0.00 Revenue from IRIS Pharma 1.40 1.09 T